ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > Best in Class/ Worst in performance

<< Previous

Bullboard Posts

Next >>

Comment by FarmerBetsyon Oct 16, 2024 8:46pm

126 Views

Post# 36269211

RE:RE:RE:RE:RE:RE:RE:Best in Class/ Worst in performance

Looks like another 10% owner.. I think that's four now, i'm sure 5 or 6 now owe greater than 50%

Shaf QIC LLC reported by Jonathon Shafmaster, is that to do with director Maggie Shafmaster and their is the reason for all time low plaecments and stock price. Low institutional ownership, this company controlled by a handful of investors.

<< Previous

Bullboard Posts

Next >>

Understanding tax loss season and the “Santa Claus rally”